The burden of rheumatoid arthritis. Based on a presentation by Frederick Wolfe, MD.
The direct, indirect, and intangible costs of rheumatoid arthritis (RA) represent an enormous burden to patients, clinicians, and to society in general. Quality of life is consistently worse--at any age--for RA patients and they tend to die at younger ages. Lessening the burden may be possible through more accurate and careful measurement of quality of life, disease progression, and therapeutic outcomes. Predicting the likely progression of RA and determining which patients will show improvement and which can expect disability is important in discovering which therapeutic approaches are the most useful in ultimately lessening the burden of RA.
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000191:economics / Q000473:pathology / Q000523:psychology*; D017281:Cost of Illness; D003657:Decision Making; D006233:Persons with Disabilities; D018450:Disease Progression; D017048:Health Care Costs; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D011788:Quality of Life; D014481:United States
D018501:Antirheumatic Agents